Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. AUTL has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
AUTL stock price ended at $1.23 on Wednesday, after rising4.24%
The Autolus Therapeutics PLC stock price increased by 4.24% on the last trading day (07 May 2025), rising from 1.18 to 1.23. Throughout the last trading session, the stock experienced a fluctuation of 8.70% , ranging from a day low of $1.15 to a day high of 1.25. The price has declined in 6 of the last 10 days, resulting in a total change of -18.54% during this period. On the last day, trading volume increase by 1.05M shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 2.99M shares were traded, amounting to approximately 3.57M.
AUTL Technical Signals
AUTL(Autolus Therapeutics PLC Corp) has 4 buy signals and 4 sell signals now. The current trend is downtrend starting from 2025-04-23. The total price change during this trend is -18.54%. Recently, the price has increased significantly with an increase in volume, indicating a strong bullish signal. The average turnover of AUTL over the last 5 trading days is 2.73M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
AUTL Moving Average Analysis
Autolus Therapeutics PLC's overall moving average trend leans more bearish as of Thursday, May 8, 2025, with 4 negative signals and 0 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $1.5993800000000002, and $1.7560000000000002. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $1.09262, and $0.9359999999999999. A break-down below any of these levels will issue sell signals.
AUTL Short Selling Analysis
The short sale ratio of Autolus Therapeutics PLC(AUTL) as of 06 May 2025 is 28.22%, rising from last trading day. With increasing price from 1.33 to 1.18. The short sell activity indicate that short sellers may be anticipating further declines.
Technical Signal
Technical Signals Summary
Neutral
Sell
4
Buy
4
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
4 Bullish Signals
4 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 < 20
9.429
Bullish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 < -100
-130.553
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
12.615
Bullish
Williams %R (14 days)
WILLR_14 < -80
-85.965
Bullish
4 Bearish Signals
4 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 < 0
-0.131
Bearish
Momentum (10 days)
MOM_10 < 0
-0.28
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.0802
Bearish
Moving Average
10-day SMA crosses below 20-day SMA
--
Bearish
AUTL Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Autolus Therapeutics PLC(AUTL), our algorithm predicts AUTL's 1-month price at $1.56, with an 15.69%upwardshift. Using a similarity score up to 93.41%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Autolus Therapeutics PLC (AUTL.O) stock, as of Sunday, May 4, 2025 , forecasts a 15.69% change over the next month, based on its high correlation with XHR.N stock patterns. The similarity between their price movements over the analyzed periods is 93.41%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
AUTL
Future prediction
Up: 15.69%
XHR
Up: 15.69%Similarity: 93.41%
Name
Similarity
Up/Down
XHR.N
93.41%
+15.69%
OPTN.O
93.09%
-19.20%
CUBE.N
93.06%
+10.79%
CDNA.O
93.04%
-11.44%
RGNX.O
92.88%
+23.79%
OLLI.O
92.88%
+22.05%
WK.N
92.85%
+21.91%
DENN.O
92.80%
+5.95%
CARV.O
92.76%
+0.56%
SLNO.O
92.67%
+9.82%
AUTL Seasonality Analysis
Based on AUTL's historical stock price data across all years, the probability of a positive return in May is57.14%, suggesting it maybe an ideal month to invest in AUTL. In contrast,Mayoffers the highest probability of positive returns at57.14%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Autolus Therapeutics PLC (AUTL.O) stock in May has the highest probability of a positive return (57.14%), while January has the lowest probability (14.29%).
Performance Seasonality
The chart shows Autolus Therapeutics PLC. (AUTL)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
Should I buy Autolus Therapeutics PLC (AUTL.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. AUTL has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Autolus Therapeutics PLC (AUTL.O) stock in a year?
The radar chart shows that buying Autolus Therapeutics PLC (AUTL.O) stock in May has the highest probability of a positive return (57.14%), while January has the lowest probability (14.29%).
How has Autolus Therapeutics PLC. (AUTL)'s stock price performed over the past three years?
AUTL's stock price rose by 244.39% in 2023,decreased by -65.64% in 2024, and went down by 53.23% in 2025.
Is AUTL a buy based on overall technical signals summary?
AUTL has 4 buy signals and 4 sell signals now. Overall the technical rating for AUTL is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of AUTL.
What is the trend of Autolus Therapeutics PLC (AUTL)'s moving average?
Autolus Therapeutics PLC's overall moving average trend leans more bearish as of May 08 2025, with 4 negative signals and 0 positive signal.
What is price prediction for AUTL stock next month?
The price prediction chart for Autolus Therapeutics PLC (AUTL.O) stock, as of May 04 2025, forecasts a 15.69% change over the next month, based on its high correlation with XHR stock patterns. The similarity between their price movements over the analyzed periods is 93.41%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for AUTL Stock?
### **Price Prediction for AUTL Stock in 2025**
The price prediction for AUTL stock in 2025 is **$1.50 to $2.00** in the short term, driven by positive catalysts such as the ASH meeting presentation and analyst upgrades. However, without earnings, the stock may dip to **$1.20** if results underperform.
What is price prediction 2030 for AUTL Stock?
AUTL stock is predicted to reach **$10.00 by 2030**, driven by positive clinical data from the FELIX trial and an analyst upgrade to Buy with a 252.43% upside target. The stock is currently undervalued with strong institutional ownership growth.